Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Greenwich Lifesciences Inc (NQ: GLSI )

8.960 +0.490 (+5.79%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 57,786
Open 8.390
Bid (Size) 8.260 (4)
Ask (Size) 8.960 (1)
Prev. Close 8.470
Today's Range 8.108 - 9.150
52wk Range 6.824 - 48.50
Shares Outstanding 101,440,840
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Why Is Ceragon Networks Surging By 19%? 41 Stocks Moving In Tuesday's Mid-Day Session
Gainers Agile Therapeutics, Inc. (NASDAQ: AGRX) jumped 88.9% to $2.3986. Agile Therapeutics shares climbed over 10% on Monday amid the Supreme Court overturning Roe V Wade. 
Via Benzinga
Greenwich LifeSciences to Resume Stock Repurchase Program
From Greenwich LifeSciences, Inc.
Via Business Wire

Performance

YTD
-62.03%
-62.03%
1 Month
+13.71%
+13.71%
3 Month
-55.99%
-55.99%
6 Month
-62.03%
-62.03%
1 Year
-79.21%
-79.21%

More News

Read More
Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting
From Greenwich LifeSciences, Inc.
Via Business Wire
91 Biggest Movers From Friday
Via Benzinga
69 Biggest Movers From Yesterday
Via Benzinga
Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences
From Greenwich LifeSciences, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer
From Greenwich LifeSciences, Inc.
Via Business Wire
Recession Fears are Creating a Golden Opportunity for Biotech Stocks
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01
From Greenwich LifeSciences, Inc.
Via Business Wire
78 Biggest Movers From Friday
Via Benzinga
3 Stocks Insiders Are Buying on Market Turbulence
Via InvestorPlace
62 Biggest Movers From Yesterday
Via Benzinga
Greenwich LifeSciences to Implement Stock Repurchase Program for up to $10 Million & to Extend Lock-up of Insiders for an Additional 1 Year
From Greenwich LifeSciences, Inc.
Via Business Wire
65 Biggest Movers From Yesterday
Via Benzinga
Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences Reveals 5-Year Data for GP2 Immunotherapy In Breast Cancer Settings
Via Benzinga
Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences to Participate in Multiple Interviews and Conferences
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences Expands Role of Industry Expert Dr. F. Joseph Daugherty to Include Medical Monitor for its Upcoming Phase III Clinical Trial
From Greenwich LifeSciences, Inc.
Via Business Wire
Greenwich LifeSciences Announces Commencement of the First Commercial Line Filling of GP2
From Greenwich LifeSciences, Inc.
Via Business Wire
58 Biggest Movers From Friday
Via Benzinga
Greenwich LifeSciences CEO Interview to Air on Bloomberg U.S. on the RedChip Money Report
From Greenwich LifeSciences, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.